Markets:

Overview

News

Currencies

International

Treasuries

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

2.331 -0.039 (-1.65%)

Streaming Delayed Price Updated: 10:18 AM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Spero Therapeutics Inc (NASDAQ:SPRO) Reports Q4 Earnings Beat and Positive Regulatory Step ↗

March 26, 2026

Via Chartmill

Topics Earnings

Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat ↗

November 13, 2025

Spero Therapeutics (SPRO) smashed Q3 2025 earnings, with revenue of $5.44M beating $0 estimates and a narrower EPS loss of -$0.13.

Via Chartmill

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Insights Ahead: Spero Therapeutics's Quarterly Earnings ↗

November 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 12, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

August 12, 2025

After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Earnings Outlook For Spero Therapeutics ↗

August 11, 2025

Via Benzinga

An Overview of Spero Therapeutics's Earnings ↗

May 12, 2025

Via Benzinga

SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline ↗

August 12, 2025

SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy.

Via Chartmill

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 09, 2025

Via Benzinga

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 30, 2025

Via Benzinga

A Glimpse of Spero Therapeutics's Earnings Potential ↗

March 26, 2025

Via Benzinga

The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts ↗

January 30, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Spero Therapeutics ↗

December 20, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Unusual volume stocks in Friday's session ↗

May 30, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

May 29, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

These stocks are making the most noise in today's session. ↗

May 28, 2025

Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 28, 2025

Via Benzinga

Spero Therapeutics's Earnings Outlook ↗

November 13, 2024

Via Benzinga

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast ↗

May 28, 2025

Via Benzinga

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? ↗

May 28, 2025

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.

Via Benzinga

US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings ↗

May 28, 2025

Via Benzinga

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled ↗

May 28, 2025

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.